MedKoo product information:

 Decitabine

Dacogen (decitabine) for Injection contains decitabine (5-aza-2'deoxycitidine), an analogue of the natural nucleoside 2'-deoxycytidine. Decitabine is a fine, white to almost white powder with the molecular formula of C8H12N4O4 and a molecular weight of 228.21. Its chemical name is 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin2(1H)-one. Decitabine is slightly soluble in ethanol/water (50/50), methanol/water (50/50) and methanol; sparingly soluble in water and soluble in dimethylsulfoxide (DMSO).

Dacogen (decitabine) for Injection is a white to almost white sterile lyophilized powder supplied in a clear colorless glass vial. Each 20 mL, single dose, glass vial contains 50 mg decitabine, 68 mg monobasic potassium phosphate (potassium dihydrogen phosphate) and 11.6 mg sodium hydroxide.

Decitabine is indicated for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups.

Mechanism of Action

Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation or apoptosis. Decitabine inhibits DNA methylation in vitro , which is achieved at concentrations that do not cause major suppression of DNA synthesis. Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical for the control of cellular differentiation and proliferation. In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA. Non-proliferating cells are relatively insensitive to decitabine.

  1: Quintás-Cardama A, Santos FP, Garcia-Manero G; Medscape. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20551943.

2: Galili N, Raza A. Pharmacotherapy of myelodysplastic syndromes. Expert Opin Pharmacother. 2010 May 20. [Epub ahead of print] PubMed PMID: 20486832.

3: Blum KA, Liu Z, Lucas DM, Chen P, Xie Z, Baiocchi R, Benson DM, Devine SM, Jones J, Andritsos L, Flynn J, Plass C, Marcucci G, Chan KK, Grever MR, Byrd JC. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol. 2010 Apr 29. [Epub ahead of print] PubMed PMID: 20456354.

4: Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, Dipersio JF. In vivo administration of hypomethylating agents mitigate graft-versus-host disease (GvHD) without sacrificing graft-versus-leukemia (GvL). Blood. 2010 Apr 27. [Epub ahead of print] PubMed PMID: 20424188.

5: Zhu X, Ma Y, Liu D. Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights. J Hematol Oncol. 2010 Apr 23;3:17. PubMed PMID: 20416083; PubMed Central PMCID: PMC2880983.

6: Cang S, Lu Q, Ma Y, Liu D. Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets. 2010 Aug;10(5):539-45. PubMed PMID: 20384584.

7: Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res. 2010 Jul;34(7):899-905. Epub 2010 Apr 10. PubMed PMID: 20381863.

8: Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. Review. PubMed PMID: 20359633.

9: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. PubMed PMID: 20094643.

10: Kogan AJ, Dunn JD. Myelodysplastic syndromes: health care management considerations. Manag Care. 2009 Nov;18(11 Suppl 9):25-8; discussion 28-9. PubMed PMID: 20085114.

11: Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res. 2010;184:131-57. Review. PubMed PMID: 20072836.

12: Krug U, Lübbert M, Büchner T. Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest? Curr Opin Hematol. 2010 Mar;17(2):85-90. Review. PubMed PMID: 20061945.

13: Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010 Feb 1;28(4):605-13. Epub 2009 Dec 28. Erratum in: J Clin Oncol. 2010 Jun 20;28(18):3098. PubMed PMID: 20038729; PubMed Central PMCID: PMC2815995.

14: Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22. Review. PubMed PMID: 20014881.

15: Sekeres MA. Treatment of MDS: something old, something new, something borrowed... Hematology Am Soc Hematol Educ Program. 2009:656-63. Review. PubMed PMID: 20008251.

16: Gore SD. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment? Leuk Res. 2009 Dec;33 Suppl 2:S2-6. PubMed PMID: 20004793.

17: Steensma DP. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk Res. 2009 Dec;33 Suppl 2:S12-7. PubMed PMID: 20004791.

18: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Oct;31(8):541-57. PubMed PMID: 19967103.

19: Stone R, Sekeres M, Garcia-Manero G. Evolving strategies in the treatment of MDS and AML. Clin Adv Hematol Oncol. 2009 Aug;7(8):1-14; quiz 2 p following 14. PubMed PMID: 19927982.

20: Ishikawa T. [Novel therapeutic agents for myelodysplastic syndrome]. Rinsho Ketsueki. 2009 Oct;50(10):1553-9. Review. Japanese. PubMed PMID: 19915366.

21: Yokoyama H, Harigae H. [Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. Nippon Rinsho. 2009 Oct;67(10):1974-7. Review. Japanese. PubMed PMID: 19860200.

22: Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol. 2010 Feb;116(2):195-201. Epub 2009 Oct 24. Review. PubMed PMID: 19854495; PubMed Central PMCID: PMC2813995.

23: Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 2010 Feb;95(2):340-2; author reply 343-4. Epub 2009 Oct 22. PubMed PMID: 19850902; PubMed Central PMCID: PMC2817042.

24: Gurion R, Vidal L, Gafter-Gvili A, Belnik Y, Yeshurun M, Raanani P, Shpilberg O. 5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis. Haematologica. 2010 Feb;95(2):303-10. Epub 2009 Sep 22. PubMed PMID: 19773261; PubMed Central PMCID: PMC2817034.

25: Tuma RS. Epigenetic therapies move into new territory, but how exactly do they work? J Natl Cancer Inst. 2009 Oct 7;101(19):1300-1. Epub 2009 Sep 15. PubMed PMID: 19755677.

26: Silverman LR. Clinical roundtable monograph. Overall survival and maintenance of MDS patients. Clin Adv Hematol Oncol. 2009 Jul;7(7):S3-5. PubMed PMID: 19708287.

27: Li Q, Bartlett DL, Gorry MC, O'Malley ME, Guo ZS. Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol. 2009 Nov;76(5):1072-81. Epub 2009 Aug 13. PubMed PMID: 19679824.

28: Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2009 Sep;84(9):599-600. PubMed PMID: 19650144.

29: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 May;31(4):263-98. PubMed PMID: 19557204.

30: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PubMed PMID: 19536362.

31: Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009 Jun 15;15(12):3938-46. Epub 2009 Jun 9. PubMed PMID: 19509174; PubMed Central PMCID: PMC2732562.

32: Hemavathy K, Wang JC. Epigenetic modifications: new therapeutic targets in primary myelofibrosis. Curr Stem Cell Res Ther. 2009 Dec;4(4):281-6. Review. PubMed PMID: 19500065.

33: Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW, Sowers LC. Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol. 2009 Jun;22(6):1194-204. PubMed PMID: 19480391.

34: Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Tannir N, Horne E, Groshen S, Jones P, Yang A, Issa JP. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics. 2009 Apr;4(3):176-84. Epub 2009 Apr 6. PubMed PMID: 19421002; PubMed Central PMCID: PMC2848123.

35: Stone R, Sekeres M, Garcia-Manero G, Lyons RM. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy. Clin Adv Hematol Oncol. 2008 Dec;6(12):1-15. PubMed PMID: 19385003.

36: Stone RM. How I treat patients with myelodysplastic syndromes. Blood. 2009 Jun 18;113(25):6296-303. Epub 2009 Apr 21. Review. PubMed PMID: 19383969.

37: Raghupathy R, Billett HH. Promising therapies in sickle cell disease. Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):1-8. Review. PubMed PMID: 19275572.

38: Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Lübbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28. Epub 2009 Feb 5. PubMed PMID: 19194470.

39: Scott BL, Estey E. Management of myelodysplastic syndromes: 2008 update. Oncology (Williston Park). 2008 Nov 15;22(12):1344-52. Review. PubMed PMID: 19086598; PubMed Central PMCID: PMC2647329.

40: Trompeter S, Roberts I. Haemoglobin F modulation in childhood sickle cell disease. Br J Haematol. 2009 Feb;144(3):308-16. Epub 2008 Nov 20. Review. PubMed PMID: 19036119.

41: Wang WC. The pharmacotherapy of sickle cell disease. Expert Opin Pharmacother. 2008 Dec;9(17):3069-82. Review. PubMed PMID: 19006479.

42: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183.

43: Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control. 2008 Oct;15 Suppl:40-9. Review. PubMed PMID: 18813208; PubMed Central PMCID: PMC2727156.

44: Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008 Nov;20(6):705-10. Review. PubMed PMID: 18841054.

45: Miyazawa K. [Pathogenesis of and therapeutic progress for myelodysplastic syndromes]. Rinsho Ketsueki. 2008 Oct;49(10):1358-67. Review. Japanese. PubMed PMID: 18833920.

46: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jun;30(5):383-408. PubMed PMID: 18806898.

47: Müller-Thomas C, Schuster T, Peschel C, Götze KS. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009 Mar;88(3):213-9. Epub 2008 Aug 12. PubMed PMID: 18696067.

48: Festuccia C, Gravina GL, D'Alessandro AM, Millimaggi D, Di Rocco C, Dolo V, Ricevuto E, Vicentini C, Bologna M. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells. Int J Oncol. 2008 Aug;33(2):381-8. PubMed PMID: 18636160.

49: Srinivasan S, Schiffer CA. Current treatment options and strategies for myelodysplastic syndromes. Expert Opin Pharmacother. 2008 Jul;9(10):1667-78. Review. PubMed PMID: 18570600.

50: Perrine SP. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr Ann. 2008 May;37(5):339-46. Review. PubMed PMID: 18543545.

51: Yu N, Wang M. Anticancer drug discovery targeting DNA hypermethylation. Curr Med Chem. 2008;15(14):1350-75. Review. PubMed PMID: 18537614.

52: Oki Y, Issa JP. Review: recent clinical trials in epigenetic therapy. Rev Recent Clin Trials. 2006 May;1(2):169-82. Review. PubMed PMID: 18473969.

53: Lemaire M, Chabot GG, Raynal NJ, Momparler LF, Hurtubise A, Bernstein ML, Momparler RL. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer. BMC Cancer. 2008 May 2;8:128. PubMed PMID: 18454857; PubMed Central PMCID: PMC2386792.

54: Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. 2008 Jun;112(11):2341-51. Review. PubMed PMID: 18398832.

55: Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol. 2008 Aug;87(8):601-11. Epub 2008 Apr 5. Review. PubMed PMID: 18392623.

56: Schwabe M, Lübbert M. Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol. 2007 Dec;8(6):382-7. Review. PubMed PMID: 18289047.

57: Garcia-Manero G, Yang AS, Jagasia M. Evaluating new treatment options for MDS. Clin Adv Hematol Oncol. 2007 Nov;5(11):1-9; quiz 10-2. Review. PubMed PMID: 18185491.

58: Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol. 2008 Jan;45(1):23-30. Review. PubMed PMID: 18179966; PubMed Central PMCID: PMC2234265.

59: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Oct;29(8):547-83. PubMed PMID: 18040531.

60: Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4603-9. PubMed PMID: 17925555.

61: Plimack ER, Stewart DJ, Issa JP. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol. 2007 Oct 10;25(29):4519-21. PubMed PMID: 17925545.

62: Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008 Apr;32(4):587-91. Epub 2007 Sep 18. PubMed PMID: 17881052.

63: Al-Romaih K, Somers GR, Bayani J, Hughes S, Prasad M, Cutz JC, Xue H, Zielenska M, Wang Y, Squire JA. Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: identification of apoptotic genes as targets for demethylation. Cancer Cell Int. 2007 Sep 10;7:14. PubMed PMID: 17845729; PubMed Central PMCID: PMC2034371.

64: Kihslinger JE, Godley LA. The use of hypomethylating agents in the treatment of hematologic malignancies. Leuk Lymphoma. 2007 Sep;48(9):1676-95. Review. PubMed PMID: 17786703.

65: Plimack ER, Kantarjian HM, Issa JP. Decitabine and its role in the treatment of hematopoietic malignancies. Leuk Lymphoma. 2007 Aug;48(8):1472-81. Review. PubMed PMID: 17701577.

66: Lavelle D, Chin J, Vaitkus K, Redkar S, Phiasivongsa P, Tang C, Will R, Hankewych M, Roxas B, Singh M, Saunthararajah Y, Desimone J. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am J Hematol. 2007 Nov;82(11):981-5. PubMed PMID: 17696208.

67: Atallah E, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol. 2007 Jul;5(7):544-52. Review. PubMed PMID: 17679928.

68: Giagounidis AA. Decitabine dosage in myelodysplastic syndromes. Blood. 2007 Aug 1;110(3):1082-3; author reply 1083. PubMed PMID: 17644750.

69: Rüter B, Wijermans P, Claus R, Kunzmann R, Lübbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood. 2007 Aug 1;110(3):1080-2; author reply 1083. PubMed PMID: 17644749.

70: Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc). 2007 Jun;43(6):395-422. Review. PubMed PMID: 17612710.

71: Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007 May 10;25(14):1908-15. Review. PubMed PMID: 17488990.

72: Brueckner B, Kuck D, Lyko F. DNA methyltransferase inhibitors for cancer therapy. Cancer J. 2007 Jan-Feb;13(1):17-22. Review. PubMed PMID: 17464242.

73: Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer. 2007 May 15;109(10):2132-41. PubMed PMID: 17407132.

74: Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007 Mar 15;13(6):1634-7. Review. PubMed PMID: 17363514.

75: Schiffer CA. Myelodysplasia: the good, the fair and the ugly. Best Pract Res Clin Haematol. 2007 Mar;20(1):49-55. Review. PubMed PMID: 17336254.

76: Sekeres MA. The myelodysplastic syndromes. Expert Opin Biol Ther. 2007 Mar;7(3):369-77. Review. PubMed PMID: 17309328.

77: Liu Z, Liu S, Xie Z, Blum W, Perrotti D, Paschka P, Klisovic R, Byrd J, Chan KK, Marcucci G. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res. 2007;35(5):e31. Epub 2007 Jan 30. PubMed PMID: 17264127; PubMed Central PMCID: PMC1865075.

78: Cilloni D, Messa E, Messa F, Carturan S, Defilippi I, Arruga F, Rosso V, Catalano R, Bracco E, Nicoli P, Saglio G. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes. Ann N Y Acad Sci. 2006 Nov;1089:411-23. Review. PubMed PMID: 17261784.

79: Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res. 2007 Jan 1;67(1):346-53. PubMed PMID: 17210717.

80: Atallah E, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review. PubMed PMID: 17163808.

81: Raza A, Raza FZ, Galili N. Low-dose decitabine and high-risk MDS. Blood. 2006 Dec 15;108(13):4291; author reply 4291-2. PubMed PMID: 17148594.

82: Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:58-62. Review. PubMed PMID: 17124041.

83: Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT. Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31. Epub 2006 Nov 6. PubMed PMID: 17088539; PubMed Central PMCID: PMC1859945.

84: Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst. 2006 Oct 18;98(20):1443-4. PubMed PMID: 17047192.

85: Oki Y, Aoki E, Issa JP. Decitabine--bedside to bench. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. Epub 2006 Oct 4. Review. PubMed PMID: 17023173.

86: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851.

87: Hurtubise A, Momparler RL. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother Pharmacol. 2006 Nov;58(5):618-25. Epub 2006 Jun 17. PubMed PMID: 16783580.

88: Kantarjian HM, Cortes J. New strategies in chronic myeloid leukemia. Int J Hematol. 2006 May;83(4):289-93. Review. PubMed PMID: 16757426.

89: Garcia-Manero G, Saba HI. Decitabine in myelodysplastic syndromes: viewpoints. Drugs. 2006;66(7):959-60. PubMed PMID: 16740015.

90: McKeage K, Croom KF. Decitabine: in myelodysplastic syndromes. Drugs. 2006;66(7):951-8. PubMed PMID: 16740014.

91: Wijermans P, Lübert M. Epigenetic therapy with decitabine for myelodysplasia and leukemia. Future Oncol. 2005 Oct;1(5):585-91. Review. PubMed PMID: 16556035.

92: Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006 Apr 15;106(8):1744-50. PubMed PMID: 16532502.

93: List AF. New agents in the treatment of MDS. Clin Adv Hematol Oncol. 2005 Nov;3(11):832-4. PubMed PMID: 16491623.

94: Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006 Jan;81(1):104-30. Review. PubMed PMID: 16438486.

95: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Nov;27(9):665-77. PubMed PMID: 16357953.

96: Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S36-44. Review. PubMed PMID: 16341239.

97: Hellström-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigenetic-acting agents. Hematology Am Soc Hematol Educ Program. 2005:161-6. PubMed PMID: 16304375.

98: Hackanson B, Robbel C, Wijermans P, Lübbert M. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Ann Hematol. 2005 Dec;84 Suppl 1:32-8. Review. PubMed PMID: 16292549.

99: Yee KW, Jabbour E, Kantarjian HM, Giles FJ. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Ann Hematol. 2005 Dec;84 Suppl 1:18-24. PubMed PMID: 16273408.

100: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Oct;27(8):569-612. PubMed PMID: 16273137.

101: Rosenfeld CS. Clinical development of decitabine as a prototype for an epigenetic drug program. Semin Oncol. 2005 Oct;32(5):465-72. Review. PubMed PMID: 16210087.

102: Murgo AJ. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs. Semin Oncol. 2005 Oct;32(5):458-64. Review. PubMed PMID: 16210086.

103: Momparler RL. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine). Semin Oncol. 2005 Oct;32(5):443-51. Review. PubMed PMID: 16210084.

104: Hubeek I, Peters GJ, Broekhuizen AJ, Sargent J, Gibson BE, Creutzig U, Kaspers GJ. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia. Br J Haematol. 2005 Oct;131(2):219-22. PubMed PMID: 16197453.

105: DeSimone J. Approaches to the reactivation of hemoglobin F as a treatment for sickle cell disease. Clin Adv Hematol Oncol. 2004 Jan;2(1):23-4. PubMed PMID: 16163154.

106: Haas PS, Wijermans P, Verhoef G, Lübbert M. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability. Leuk Res. 2006 Mar;30(3):338-42. Epub 2005 Sep 12. PubMed PMID: 16162357.

107: Kuykendall JR. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother. 2005 Oct;39(10):1700-9. Epub 2005 Sep 6. Review. PubMed PMID: 16144884.

108: Manoharan A. Decitabine (SuperGen). IDrugs. 2000 Dec;3(12):1525-33. PubMed PMID: 16037861.

109: Issa JP, Byrd JC. Decitabine in chronic leukemias. Semin Hematol. 2005 Jul;42(3 Suppl 2):S43-9. Review. PubMed PMID: 16015505.

110: Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin Hematol. 2005 Jul;42(3 Suppl 2):S17-22. Review. Erratum in: Semin Hematol. 2005 Oct;42(4):274. PubMed PMID: 16015500.

111: Digel W, Lübbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol. 2005 Jul;55(1):1-11. Review. PubMed PMID: 15886007.

112: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jan-Feb;27(1):49-77. PubMed PMID: 15834459.

113: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):193-219. PubMed PMID: 15834452.

114: Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS. Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene. 2005 Mar 31;24(14):2386-97. PubMed PMID: 15735751.

115: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):801-27. PubMed PMID: 15672123.

116: Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res. 2004 Dec 15;64(24):9167-71. PubMed PMID: 15604288.

117: Arthur C. Decitabine. MGI Pharma Inc/SuperGen Inc. IDrugs. 2004 Dec;7(12):1113-32. Review. PubMed PMID: 15599805.

118: Szafraniec SI, Stachnik KJ, Skierski JS. New nucleoside analogs in the treatment of solid tumors. Acta Pol Pharm. 2004 Jul-Aug;61(4):297-305. Review. PubMed PMID: 15575597.

119: DeBaun MR. Issues regarding study design for initial clinical trials using decitabine. Semin Hematol. 2004 Oct;41(4 Suppl 6):23-7. PubMed PMID: 15534854.

120: Lal A, Vichinsky E. The role of fetal hemoglobin-enhancing agents in thalassemia. Semin Hematol. 2004 Oct;41(4 Suppl 6):17-22. Review. PubMed PMID: 15534853.

121: Szafraniec SI, Stachnik KJ, Skierski JS. New nucleoside analogs in the treatment of hematological disorders. Acta Pol Pharm. 2004 May-Jun;61(3):223-32. Review. PubMed PMID: 15481249.

122: Saunthararajah Y, Lavelle D, DeSimone J. DNA hypo-methylating agents and sickle cell disease. Br J Haematol. 2004 Sep;126(5):629-36. Review. PubMed PMID: 15327513.

123: Hurtubise A, Momparler RL. Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anticancer Drugs. 2004 Feb;15(2):161-7. PubMed PMID: 15075673.

124: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PubMed PMID: 15071612.

125: Dowell JE, Minna JD. Cancer chemotherapy targeted at reactivating the expression of epigenetically inactivated genes. J Clin Oncol. 2004 Apr 15;22(8):1353-5. Epub 2004 Mar 8. PubMed PMID: 15007082.

126: Lyons J, Bayar E, Fine G, McCullar M, Rolens R, Rubinfeld J, Rosenfeld C. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50. Review. PubMed PMID: 14763130.

127: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Nov;25(9):747-71. PubMed PMID: 14685303.

128: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Oct;25(8):653-82. PubMed PMID: 14671684.

129: Hennessy BT, Garcia-Manero G, Kantarjian HM, Giles FJ. DNA methylation in haematological malignancies: the role of decitabine. Expert Opin Investig Drugs. 2003 Dec;12(12):1985-93. Review. PubMed PMID: 14640942.

130: Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2003:176-99. Review. PubMed PMID: 14633782.

131: Issa JP. Decitabine. Curr Opin Oncol. 2003 Nov;15(6):446-51. Review. PubMed PMID: 14624227.

132: Leone G, Voso MT, Teofili L, Lübbert M. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003 Oct;109(1):89-102. Review. PubMed PMID: 14585280.

133: Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D. 2003;4(6):352-8. Review. PubMed PMID: 14584964.

134: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408. PubMed PMID: 12851663.

135: Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D. 2003;4(3):179-84. Review. PubMed PMID: 12757405.

136: Shaker S, Bernstein M, Momparler LF, Momparler RL. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003 May;27(5):437-44. PubMed PMID: 12620295.

137: Decitabine has promising clinical activity in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2002 Dec;2(6):620-1. PubMed PMID: 12503205.

138: Leone G, Teofili L, Voso MT, Lübbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002 Dec;87(12):1324-41. Review. PubMed PMID: 12495905.

139: Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2003 Jan 10;103(2):177-84. PubMed PMID: 12455031.

140: Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program. 2002:111-35. Review. PubMed PMID: 12446421.

141: Aul C, Giagounidis A, Germing U, Ganser A. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies]. Med Klin (Munich). 2002 Nov 15;97(11):666-76. Review. German. PubMed PMID: 12434275.

142: Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr Opin Investig Drugs. 2002 Apr;3(4):627-33. Review. PubMed PMID: 12090735.

143: Garcia-Manero G, Talpaz M, Kantarjian HM. Current therapy of chronic myelogenous leukemia. Intern Med. 2002 Apr;41(4):254-64. Review. PubMed PMID: 11993784.

144: Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. Cancer Res. 2002 Feb 15;62(4):961-6. PubMed PMID: 11861364.

145: Matsuo T, Tomonaga M. [Chemotherapy and radiation therapy]. Nippon Rinsho. 2001 Dec;59(12):2364-8. Review. Japanese. PubMed PMID: 11766340.

146: Karpf AR, Moore BC, Ririe TO, Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. Mol Pharmacol. 2001 Apr;59(4):751-7. PubMed PMID: 11259619.

147: Cheson BD, Zwiebel JA, Dancey J, Murgo A. Novel therapeutic agents for the treatment of myelodysplastic syndromes. Semin Oncol. 2000 Oct;27(5):560-77. Review. PubMed PMID: 11049023.

148: Bovenzi V, Momparler RL. Quantitation of inhibition of DNA methylation of the retinoic acid receptor beta gene by 5-Aza-2'-deoxycytidine in tumor cells using a single-nucleotide primer extension assay. Anal Biochem. 2000 May 15;281(1):55-61. PubMed PMID: 10847610.

149: Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs. 2000 Feb;18(1):83-91. PubMed PMID: 10830142.

150: Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol. 2000;249:135-64. Review. PubMed PMID: 10802943.

151: dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN, van Kessel AG. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 2000 Mar 15;60(6):1654-62. PubMed PMID: 10749136.

152: Quesnel B, Fenaux P. P15INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma. 1999 Nov;35(5-6):437-43. Review. PubMed PMID: 10609781.

153: Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy. Hematol Oncol Clin North Am. 1998 Feb;12(1):31-80. Review. PubMed PMID: 9523225.

154: Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res. 1994 Jan-Feb;14(1A):247-51. PubMed PMID: 7513143.

155: Côté S, Momparler RL. Evaluation of the antineoplastic activity of adozelesin alone and in combination with 5-aza-2'-deoxycytidine and cytosine arabinoside on DLD-1 human colon carcinoma cells. Anticancer Drugs. 1993 Jun;4(3):327-33. PubMed PMID: 7689364.

156: Gattei V, Aldinucci D, Petti MC, Da Ponte A, Zagonel V, Pinto A. In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients. Leukemia. 1993 May;7 Suppl 1:42-8. PubMed PMID: 7683356.

157: Momparler RL, Doré BT, Labiberté J, Momparler LF. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase. Leukemia. 1993 May;7 Suppl 1:17-20. PubMed PMID: 7683351.

158: Clavel M, Monfardini S, Fosså S, Smyth J, Renard J, Kaye SB. 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Ann Oncol. 1992 May;3(5):399-400. PubMed PMID: 1377488.

159: Frost P, Abbruzzese JL, Hunt B, Lee D, Ellis M. Synergistic cytotoxicity using 2'-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res. 1990 Aug 1;50(15):4572-7. PubMed PMID: 1695122.

160: Jehn U. New approaches in the treatment of MDS: an overview of current trials. Acta Haematol Pol. 1990 Jul-Dec;21(2):129-38. PubMed PMID: 1719727.

161: Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F. Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. Eur J Cancer. 1990 Feb;26(2):137-8. PubMed PMID: 1691012.

162: Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1921-4. PubMed PMID: 2449354.

163: van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986 Sep;46(9):4831-6. PubMed PMID: 2425959.

164: Chabot GG, Momparler RL. Effects of 5-aza-2'-deoxycytidine on survival and cell cycle progression of L1210 leukemia cells. Leuk Res. 1986;10(5):533-7. PubMed PMID: 2423812.

165: Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30(3):277-86. PubMed PMID: 2433702.

166: Ellims PH. Thymidine as an anticancer agent, alone or in combination. A biochemical appraisal. Cancer Chemother Pharmacol. 1982 Dec;10(1):1-6. Review. PubMed PMID: 6186411.

167: Momparler RL, Frith CH. Toxicology in mice of the antileukemic agent 5-aza-2'-deoxycytidine. Drug Chem Toxicol. 1981;4(4):373-81. PubMed PMID: 6178576.